Intragastric Balloon for Treatment of Overweight and Obesity: Which is the Best Filling Volume?

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorMater Olbia Hospital

About this trial

TITLE: Randomized study conducted in a single center, with the aim of comparing the three main filling volumes of the intragastric balloon in overweight or obese patients (BMI \>27 and \<60 kg/m2).

OBJECTIVE: To establish the efficacy and safety of the intragastric balloon inflated to different volumes in patients who are candidates for balloon placement for overweight or obesity. To date there is no well-defined filling volume and each Endoscopist inflates the balloon to a random volume between 500 and 700 ml according to the experience acquired, but without a clear rationale.

DESIGN: All overweight or obese patients with an indication for intragastric balloon placement will be preliminarily examined by a multidisciplinary team composed of a gastroeterologist, surgeon, nutritionist, psychologist, radiologist and endocrinologist.

Before each bariatric procedure, patients will undergo a psychometric and nutritional evaluation in order to identify any psychopathological conditions that contraindicate the operation.

The enrolled patients will be randomly divided to be candidates for balloon placement:

* 1/3 of patients will undergo treatment with an intragastric balloon inflated with 500 ml of saline solution and methylene blue, a space-occupying technique, which will be left in place for 1 year; * 1/3 of patients will undergo treatment with an intragastric balloon inflated with 600 ml of saline solution and methylene blue; * 1/3 of patients will undergo treatment with an intragastric balloon inflated with 700 ml of saline solution and methylene blue.

All balloons will remain in place for 6 months, as per the instructions provided in the product technical data sheet.

All the techniques described have already been widely validated by the scientific literature and are commonly used in bariatric endoscopy.

Sample size: assuming a significant level of 0.05, to detect as significant a medium effect size (f=0.25) with a power of 80% performing an ANOVA model we will need to enrol 156 patients (52 in each group). Taking into account a possible 5% of drop-out at the enrollment, the total number of patients will be around 165 (55 per group).

INFORMED CONSENT: Will be obtained upon first registration of the patient in the computer archive, as required by the hospital computer system, for access to personal data, which will be then used anonymously.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

age > 18 years, obesity grade I-III, or overweight with at least one obesity-related comorbidity

Disqualifiers

history of bariatric surgery or endoscopy, allergies to methylene blue, childbearing or not willing to participate or comply with follow-up

Trial design

Design model

Parallel

Treatments tested in this trial

  • Intragastric balloon

    Procedure/Surgery

    Randomized trial comparing fluide-filled intragastric balloon at different filling volumes.

Treatment groups

156 Participants
are divided into 3 treatment groups
Group A: Fluid filled intragastric balloon at a volume of 500 mlExperimental treatment 1 intervention
Group B: Fluid filled intragastric balloon at a volume of 600 mlExperimental treatment 1 intervention
Group C: Fluid filled intragastric balloon at a volume of 700 mlExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Weight loss defined by percentage of Total Weight Loss and Excess Weight Loss

The primary end point was weight loss defined by percentage of TWL (initial weight minus current weight) / (initial weight) x 100) and percentage EWL (initial weight minus follow-up weight) / (initial weight minus ideal weight for BMI 25) x 100%).

Time frame
From enrollment to the end of treatment at 6 months

Secondary outcomes

1

Adverse events (epigastric pain, nausea and vomiting)

Evaluation of adverse events (epigastric pain, nausea and vomiting, or any other issues (i.e., electrolyte imbalance, chest pain) after intragastric balloon placement requiring additional medical/endoscopic therapy or clinical investigation during hospitalization or until removal)

Time frame
From enrollment to the end of treatment at 6 months
2

Early balloon removal

Detection of early intragastric balloon removal

Time frame
From enrollment to the end of treatment at 6 months
3

Improvement of disease specific Quality of Life

Improvement of disease specific Quality of Life measured by EQ-5D test or Baros test

Time frame
From enrollment to the end of treatment at 6 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.